Manufacturer
GLAXO OPERATIONS UK LTD
Contents
Pazopanib HCl
Indication
Advanced renal cell carcinoma, Advanced soft tissue sarcoma.
Instruction
Should be taken on an empty stomach. Take at least 1 hr before or 2 hr after meals. Swallow whole do not chew/crush. Avoid grapefruit juice.
Drug interaction
Increased plasma concentration of midazolam, dextromethorphan (metabolites), and paclitaxel. Increased plasma concentration of uridine diphosphoglucuronosyl-transferase 1A1 (UGT1A1) substrates (e.g. irinotecan). Increased ALT levels with simvastatin. Increased risk of QT interval prolongation with concomitant use of QT-prolonging agents (e.g. haloperidol, lapatinib). Potentially Fatal: Increased risk of toxicity (e.g. pulmonary haemorrhage, gastrointestinal haemorrhage) and/or mortality with concomitant use of pemetrexed and lapatinib.Increased serum concentration with strong inhibitors of CYP3A4 (e.g. itraconazole, clarithromycin, atazanavir, nefazodone, lapatanib), P-gp, and BCRP. Decreased serum concentration with CYP3A4 inducers (e.g. rifampin), PPI (e.g. esomeprazole).
Malaysia
